Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Pharmacological manipulation of D-1-dopamine receptor function in schizophrenia
Autore:
Sedvall, GC; Karlsson, P;
Indirizzi:
Karolinska Inst, Psychiat Sect, Dept Clin Neurosci, SE-17176 Stockholm, Sweden Karolinska Inst Stockholm Sweden SE-17176 ci, SE-17176 Stockholm, Sweden
Titolo Testata:
NEUROPSYCHOPHARMACOLOGY
fascicolo: 6, volume: 21, anno: 1999, supplemento:, S
pagine: S181 - S188
SICI:
0893-133X(199912)21:6<S181:PMODRF>2.0.ZU;2-J
Fonte:
ISI
Lingua:
ENG
Soggetto:
POSITRON EMISSION TOMOGRAPHY; PRIMATE CEREBRAL-CORTEX; D2 DOPAMINE-RECEPTORS; MESSENGER-RNAS; H-3 RACLOPRIDE; CHOROID-PLEXUS; D1 RECEPTOR; HUMAN-BRAIN; SCH 23390; PET;
Keywords:
schizophrenia; dopamine; D-1 receptor; D-2 receptor; positron emission tomography (PET); autoradiography;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
55
Recensione:
Indirizzi per estratti:
Indirizzo: Sedvall, GC Karolinska Inst, Psychiat Sect, Dept Clin Neurosci, SE-17176 Stockholm, Sweden Karolinska Inst Stockholm Sweden SE-17176 Stockholm, Sweden
Citazione:
G.C. Sedvall e P. Karlsson, "Pharmacological manipulation of D-1-dopamine receptor function in schizophrenia", NEUROPSYCH, 21(6), 1999, pp. S181-S188

Abstract

The most widely accepted hypothesis concerning the pathophysiology of schizophrenia, the dopamine hypothesis, suggests that the symptoms of schizophrenia are mediated in part by a functional hyperactivity in the dopamine system in the brain, primarily at D-2-dopamine receptors. Recent data suggest that D-1-dopamine receptors may also play a major role in the pathophysiology of schizophrenia. Using positron Emission tomography (PET), increased variability and reduced D-1-receptor binding have been observed in the basal ganglia and frontal cortex of drug-naive schizophrenia patients. Such alterations have also been found in some in vitro studies. These results suggestthat the ratio of D-1- over D-2-regulated dopamine signaling in some brainregions is reduced in schizophrenia. A clinical trial of SCH 39166, a selective D-1-dopamine receptor antagonist, showed no evidence of antipsychoticactivity in schizophrenic patients. Instead, it appeared that selective D-1-receptor antagonism may have aggravated symptoms. Although these findingsdo not support the prediction that selective D-1-dopamine receptor antagonism produces antipsychotic effects, they do not preclude the possibility that combined D-1- and D-2-receptor antagonism may act synergistically to ameliorate symptoms in schizophrenia. In addition, clinical evaluation of D-1 agonists in schizophrenia should be undertaken. [Neuropsychopharmacology 22:S181-S188, 1999] (C) 1999 American College of Neuropsychopharmacology. Published by Elsevier Science Inc.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 27/01/20 alle ore 16:46:11